GlobeNewsWire
10 Jun 2026, 05:00 UTC · 5h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Sanofi is stopping the MOBILIZE phase 3 study of riliprubart in patients with CIDP due to insufficient efficacy. — The failure of a phase 3 trial represents a lost potential revenue stream and a setback for the drug's development pipeline.
-0.40The failure of the MOBILIZE study will lead Sanofi to evaluate the continuation of other riliprubart studies, including the VITALIZE phase 3 trial. — This creates uncertainty regarding the viability of the entire riliprubart program beyond the stopped study.
-0.30The termination of the MOBILIZE study will not incur significant financial costs and does not change 2026 financial guidance. — This mitigates the negative impact by confirming there is no immediate material balance sheet hit or guidance downgrade.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is stopping a phase 3 clinical study for riliprubart due to insufficient efficacy.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Seeking Alpha
5h ago
